Balanced news tone
News Sentiment
BIOA sentiment intelligence
BioAge Labs, Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
88/100 classification confidence.
directly relevant articles
high-authority source matches
-3.0% over one week, +34.9% over four weeks, trend active, and materially above fair value.
HitGen Partner BioAge Labs Doses First Participant In Phase 2 Trial Of BGE-102
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
BioAge Labs: Developing A 'Pipeline In A Pill' (NASDAQ:BIOA)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Jun 2026 07:00
- Source
- Seeking Alpha
BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102 for Cardiovascular Risk
- Tone
- Negative 42/100
- Event
- Market update
- Published
- 16 Jun 2026 12:54
- Source
- MT Newswires
BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk
- Tone
- Negative 42/100
- Event
- Market update
- Published
- 16 Jun 2026 12:00
- Source
- GlobeNewswire
BioAge Labs (BIOA) director receives 22,000 stock options at $15.48 strike
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jun 2026 07:00
- Source
- Stock Titan
BioAge Labs (BIOA) director James Healy receives 22,000 stock options at $15.48
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jun 2026 07:00
- Source
- Stock Titan
BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Disease
- Tone
- Negative 42/100
- Event
- Market update
- Published
- 06 Jun 2026 12:04
- Source
- MarketBeat
Roth Capital Partners Initiates BioAge Labs at Buy With $36 Price Target
- Tone
- Positive 58/100
- Event
- Analyst action
- Published
- 27 May 2026 10:41
- Source
- MT Newswires
BioAge Labs to Present at Upcoming Investor Conferences
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 May 2026 13:00
- Source
- GlobeNewswire
Is BioAge Labs, Inc. (BIOA) a Top Longevity Biotech Stock to Watch After New Analyst Coverage?
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 20 May 2026 07:00
- Source
- Market source
Earnings Beat: BioAge Labs, Inc. (NASDAQ:BIOA) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
- Tone
- Positive 82/100
- Event
- Earnings
- Published
- 12 May 2026 07:00
- Source
- simplywall.st
BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 08 May 2026 07:00
- Source
- GlobeNewswire
Wall Street Analysts Predict an 183.67% Upside in BioAge Labs, Inc. (BIOA): Here's What You Should Know
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 21 Apr 2026 07:00
- Source
- Market source
BGE-102 Data Inspires Confidence for BioAge Labs (BIOA)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 31 Mar 2026 07:00
- Source
- Market source
BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 24 Mar 2026 07:00
- Source
- GlobeNewswire
BioAge says oral drug cut a heart-risk marker 86% in Phase 1
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 24 Mar 2026 07:00
- Source
- Stock Titan
BioAge Labs (BIOA) Heavy Quarterly Loss Reinforces Bearish Community Narrative On Profitability
- Tone
- Negative 18/100
- Event
- Market update
- Published
- 24 Mar 2026 07:00
- Source
- simplywall.st
BioAge stock falls after announcing $75 million public offering
- Tone
- Negative 22/100
- Event
- Market update
- Published
- 20 Jan 2026 08:00
- Source
- Investing.com
2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Dec 2025 08:00
- Source
- The Motley Fool
BIOA Stock Price and Chart — NASDAQ:BIOA
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Dec 2024 08:00
- Source
- TradingView
BioAge Labs (BIOA) Stock Price, News & Analysis
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jul 2015 15:32
- Source
- MarketBeat